COVID-19 Therapeutics and Vaccines Are Here: What All Companies Need to Do Next

COVID-19 Therapeutics and Vaccines Are Here: What All Companies Need to Do Next


The pharmaceutical industry must be prepared for the coming wave of COVID-related safety reports.

The pharmaceutical industry has made COVID-19 treatments and vaccines available with unprecedented—and inspiring—speed.Although this is cause for celebration from a public health perspective, the deployment of these new products will also bring a significant new challenge for all manufacturers: an unprecedented increase in the number of safety reports that could potentially accompany the use of these new products.It is easy to imagine how this will be the case for manufacturers of products specifically for COVID-19 given they are deployed with record speed. However, manufacturers of many other products also are likely to see a significant influx of safety reports, as the new medicines and vaccines may interact with existing diseases and medicines in unforeseen ways. Therefore, it is imperative that safety teams across all companies prepare for increased demands on pharmacovigilance and risk management systems across their portfolios.

Click here to read the full article on

Request More Information

To find out more or request a demo fill in the details below:

By submitting your information, you are consenting to receive communications from MyMeds&Me. You may at any time 'opt out' of receiving these marketing communications by emailing


We use analytical cookies that need your permission. For more details and advanced options view our Cookies Policy.